Multiple SclerosisMCS-III-MOBNCT02339688
Psychometric Properties Mobility Measures MS
A study testing conventional MS rehabilitation in people with Multiple Sclerosis, run by Hasselt University at 1 site in Belgium.
Trial summary
Current study will investigate the quality (psychometric properties) and clinical utility of several mobility measures, according to disability level. Therefore, several aspects will be inquired: Was there an effect of rehabilitation Is the measure able to detect change over time? And thus the change exceed… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Sclerosis
- What is being tested?
- conventional MS rehabilitation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 254 participants
- Where
- 1 siteBelgium
- Study dates
- Oct 2014to Jun 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of MS according to McDonald criteria24,
- Expanded Disability Status Scale25 (EDSS) ≥ 2 and ≤ 6.5 as determined by neurologists or trained clinician
- no relapse within the last month
- no changes in disease modifying treatment and no corticoid-therapy within the last month
- receive at least 10 sessions of physical therapy (in- or outpatient rehabilitation), with a maximum duration of 3 months
Who cannot join
- other medical conditions interfering with mobility (e.g. stroke, pregnancy, fractures, …)
- other neurological impairments with permanent damage (stroke, Parkinson, …)
- MS-like syndromes such as neuromyelitis optica
- not able to understand and execute simple instructions
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Psychometric Properties of Mobility, Beyond Walking Speed, in Multiple Sclerosis: a Multi-center Study.
Current study will investigate the quality (psychometric properties) and clinical utility of several mobility measures, according to disability level. Therefore, several aspects will be inquired:
- Was there an effect of rehabilitation
- Is the measure able to detect change over time? And thus the change exceed measurement error and is it clinically important (responsiveness)
- Does the measure assess what it claims to measure (validity)
- Is the measure able to differentiate all performances of the patients, inclusively the very good and very bad performances (floor and ceiling effects)
- Does the measure gives similar results under consistent test conditions on another testing day (reliability) Worldwide, theoretical approaches to physical therapy and rehabilitation in Multiple Sclerosis often appear significantly different. Since the present research protocol will be performed at different centers across European countries (and US sites), this multi-center study can additionally be applied for mapping the volume and content of rehabilitation, as well as the differential impact of diverse rehabilitation approaches and training volume on mobility, for several disability levels.
Some health-economic analyses will be performed to examine what the approximate cost of rehabilitation compared to effects is and what drivers of costs are (setting, equipment, staff).
- Conditions
- Multiple Sclerosis
- Being tested
- conventional MS rehabilitation
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
conventional MS rehabilitationOther
assessment pre and post conventional MS rehabilitation
| Study group | Role | What they receive |
|---|---|---|
| convential MS rehabilitation | Other | Investigation of the quality (psychometric properties) and clinical utility of several measures of mobility Receives: Other: conventional MS rehabilitation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Timed 25-Foot Walk test (T25FW)
Measured: day 1 and at the end of the rehabilitation, an expected average of three months
Timed up and go (TUG), TUGcognitive
Measured: day 1 and at the end of the rehabilitation, an expected average of three months
Two minute walk test (2MWT)
Measured: day 1 and at the end of the rehabilitation, an expected average of three months
Four Square Step Test (FSST)
Measured: day 1 and at the end of the rehabilitation, an expected average of three months
5 repetition sit-to-stand test (5STS-test)
Measured: day 1 and at the end of the rehabilitation, an expected average of three months
Modified 5 repetition sit-to-stand test (mod 5STS-test)
Measured: day 1 and at the end of the rehabilitation, an expected average of three months
Rivermead Mobility Index (RMI)
Measured: day 1 and at the end of the rehabilitation, an expected average of three months
Multiple Sclerosis Walking Scale-12 (MSWS-12)
Measured: day 1 and at the end of the rehabilitation, an expected average of three months
Performance Scale mobility (PS-mob)
Measured: day 1 and at the end of the rehabilitation, an expected average of three months
Secondary outcomes (6)
Timed Up and Go, manual
Measured: day 1 and at the end of the rehabilitation, an expected average of three months
Berg Balance Scale (BBS)
Measured: day 1 and at the end of the rehabilitation, an expected average of three months
Dynamic Gait index (DGI)
Measured: day 1 and at the end of the rehabilitation, an expected average of three months
Activities-specific Balance Confidence Scale (ABC)
Measured: day 1 and at the end of the rehabilitation, an expected average of three months
Trunk Impairment Scale, modified Norwegian version (TIS-modNV)
Measured: day 1 and at the end of the rehabilitation, an expected average of three months
International Physical Activity Questionnaire (IPAQ)
Measured: day 1 and at the end of the rehabilitation, an expected average of three months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2015 (estimated)
- Study startOct 2014
- Primary completionDec 2015
- Study completionJun 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 254 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hasselt University
- Sponsor type
- University, hospital or other
- Collaborators
- Dept Neurological Rehabilitation Reha Zentrum Münster Gröben, National MS Center Melsbroek, Revalidatie & MS Centrum Overpelt, De Mick, Charles University, Czech Republic, Danish MS Hospitals, Haslev and Ry, Masku Neurological Rehabilitation Center, Quellenhof, Fondazione Don Carlo Gnocchi ETS, Italian Multiple Sclerosis Foundation, Sheba Medical Center, MS-Senteret Hakadal, Haukeland University Hospital, MS Rehabilitation Center Borne Sulinowo, Clinical center Belgrado, Eugenia Epalza Rehabilitation Center, Bilbao, Spain, Cleveland Mellen MS Center, University of Colorado, Denver, Queen's University, Shepherd Center, Atlanta GA, St. Louis University
- Responsible party
- Principal investigator, Peter Feys, Hasselt University
- Investigators
- Peter Feys, prof. dr., Principal investigator, Hasselt UniversityIlse Baert, Study chair, Hasselt University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02339688
- Sponsor's protocol ID
- ML10457- S56574
- Acronym
- MCS-III-MOB
- Status last verified
- Jun 2016
- First submitted
- 16 Dec 2014
- Last updated
- 14 Jun 2016
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jun 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Psychometric Properties of Mobility, Beyond Walking Speed, in Multiple Sclerosis: a Multi-center Study.
- ClinicalTrials.gov ID
- NCT02339688
- Acronym / sponsor ID
- MCS-III-MOB / ML10457- S56574
- Conditions
- Multiple Sclerosis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 254 participants (actual)
- Lead sponsor
- Hasselt UniversityUniversity, hospital or other
- Collaborators
- Dept Neurological Rehabilitation Reha Zentrum Münster Gröben, National MS Center Melsbroek, Revalidatie & MS Centrum Overpelt, De Mick, Charles University, Czech Republic, Danish MS Hospitals, Haslev and Ry, Masku Neurological Rehabilitation Center, Quellenhof, Fondazione Don Carlo Gnocchi ETS, Italian Multiple Sclerosis Foundation, Sheba Medical Center, MS-Senteret Hakadal, Haukeland University Hospital, MS Rehabilitation Center Borne Sulinowo, Clinical center Belgrado, Eugenia Epalza Rehabilitation Center, Bilbao, Spain, Cleveland Mellen MS Center, University of Colorado, Denver, Queen's University, Shepherd Center, Atlanta GA, St. Louis University
- Study start
- Oct 2014
- Primary completion
- Dec 2015 (actual)
- Study completion
- Jun 2016 (actual)
- First posted
- 15 Jan 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Current study will investigate the quality (psychometric properties) and clinical utility of several mobility measures, according to disability level. Therefore, several aspects will be inquired:
- Was there an effect of rehabilitation
- Is the measure able to detect change over time? And thus the change exceed measurement error and is it clinically important (responsiveness)
- Does the measure assess what it claims to measure (validity)
- Is the measure able to differentiate all performances of the patients, inclusively the very good and very bad performances (floor and ceiling effects)
- Does the measure gives similar results under consistent test conditions on another testing day (reliability) Worldwide, theoretical approaches to physical therapy and rehabilitation in Multiple Sclerosis often appear significantly different. Since the present research protocol will be performed at different centers across European countries (and US sites), this multi-center study can additionally be applied for mapping the volume and content of rehabilitation, as well as the differential impact of diverse rehabilitation approaches and training volume on mobility, for several disability levels.
Some health-economic analyses will be performed to examine what the approximate cost of rehabilitation compared to effects is and what drivers of costs are (setting, equipment, staff).
Study design
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| convential MS rehabilitation | Other | Other: conventional MS rehabilitationInvestigation of the quality (psychometric properties) and clinical utility of several measures of mobility |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Diagnosis of MS according to McDonald criteria24,
- Expanded Disability Status Scale25 (EDSS) ≥ 2 and ≤ 6.5 as determined by neurologists or trained clinician
- no relapse within the last month
- no changes in disease modifying treatment and no corticoid-therapy within the last month
- receive at least 10 sessions of physical therapy (in- or outpatient rehabilitation), with a maximum duration of 3 months
Key exclusion criteria (4 listed)
- other medical conditions interfering with mobility (e.g. stroke, pregnancy, fractures, …)
- other neurological impairments with permanent damage (stroke, Parkinson, …)
- MS-like syndromes such as neuromyelitis optica
- not able to understand and execute simple instructions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| conventional MS rehabilitationassessment pre and post conventional MS rehabilitation | Other | convential MS rehabilitation |
Primary outcome
Timed 25-Foot Walk test (T25FW)
Time frame: day 1 and at the end of the rehabilitation, an expected average of three months
Timed up and go (TUG), TUGcognitive
Time frame: day 1 and at the end of the rehabilitation, an expected average of three months
Two minute walk test (2MWT)
Time frame: day 1 and at the end of the rehabilitation, an expected average of three months
Four Square Step Test (FSST)
Time frame: day 1 and at the end of the rehabilitation, an expected average of three months
5 repetition sit-to-stand test (5STS-test)
Time frame: day 1 and at the end of the rehabilitation, an expected average of three months
Modified 5 repetition sit-to-stand test (mod 5STS-test)
Time frame: day 1 and at the end of the rehabilitation, an expected average of three months
Rivermead Mobility Index (RMI)
Time frame: day 1 and at the end of the rehabilitation, an expected average of three months
Multiple Sclerosis Walking Scale-12 (MSWS-12)
Time frame: day 1 and at the end of the rehabilitation, an expected average of three months
Performance Scale mobility (PS-mob)
Time frame: day 1 and at the end of the rehabilitation, an expected average of three months
6 secondary outcomes
Timed Up and Go, manual
Time frame: day 1 and at the end of the rehabilitation, an expected average of three months
Berg Balance Scale (BBS)
Time frame: day 1 and at the end of the rehabilitation, an expected average of three months
Dynamic Gait index (DGI)
Time frame: day 1 and at the end of the rehabilitation, an expected average of three months
Activities-specific Balance Confidence Scale (ABC)
Time frame: day 1 and at the end of the rehabilitation, an expected average of three months
Trunk Impairment Scale, modified Norwegian version (TIS-modNV)
Time frame: day 1 and at the end of the rehabilitation, an expected average of three months
International Physical Activity Questionnaire (IPAQ)
Time frame: day 1 and at the end of the rehabilitation, an expected average of three months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jun 2016.
Related trials for Multiple Sclerosis
RecruitingObservational study
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Progressive Multifocal Leukoencephalopathy
RecruitingObservational study
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingPhase 2/3
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
Relapsing Multiple Sclerosis
RecruitingPhase 2
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
Multiple Sclerosis
Recruiting
Dry Needling in Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Peter Feys, prof. dr. principal investigator
Hasselt University
Ilse Baert study chair
Hasselt University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing conventional MS rehabilitation in people with Multiple Sclerosis, run by Hasselt University at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jun 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Timed 25-Foot Walk test (T25FW) (time frame: day 1 and at the end of the rehabilitation, an expected average of three months). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jun 2016; AzTrials last refreshed its copy on 30 Oct 2026.